Online citations, reference lists, and bibliographies.
← Back to Search

Glycosylated Diazeniumdiolates: A Novel Class Of Enzyme-activated Nitric Oxide Donors

Xuejun Wu, X. Tang, M. Xian, P. Wang
Published 2001 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Synthetic procedures have been developed to attach the nitric oxide releasing diazeniumdiolate functional groups [N(O)NO] − to a carbohydrate unit. These glycosylated diazeniumdiolates exhibited significantly improved stability as compared to their parent diazeniumdiolate salts, yet they could readily release nitric oxide upon activation by glycosidases. Preliminary antitumor screen assay demonstrated that this class of compounds had antitumor activity.
This paper references
10.1097/00005344-199504000-00023
Nitric Oxide (NO) Donor Molecules: Effect of NO Release Rate on Vascular Smooth Muscle Cell Proliferation In Vitro
D. Mooradian (1995)
10.1002/CHIN.199839311
Nitric Oxide‐Releasing Compounds: From Basic Research to Promising Drugs
L. Keefer (1998)
10.1016/S0040-4039(01)00263-5
Synthesis of peptide-diazeniumdiolate conjugates: towards enzyme activated antitumor agents
X. Tang (2001)
10.1021/JM9701031
Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver.
J. Saavedra (1997)
10.3109/07357909809084648
In vitro screening model for the detection of agents active against myelogenous leukemia.
M. Edelstein (1998)
10.1021/JO00049A017
Secondary amine/nitric oxide complex ions, R2N[N(O)NO]-. O-functionalization chemistry
J. Saavedra (1992)
10.1097/00005344-199304000-00023
Mechanism of vascular relaxation induced by the nitric oxide (NO)/nucleophile complexes, a new class of NO-based vasodilators.
D. Morley (1993)
10.1016/S0891-5849(00)00251-3
Diazeniumdiolates: pro- and antioxidant applications of the "NONOates".
A. Fitzhugh (2000)
10.1002/(SICI)1097-0142(20000115)88:2<381::AID-CNCR20>3.0.CO;2-M
Antitumor activity of a novel glyco‐nitric oxide conjugate in ovarian carcinoma
G. Cantuaria (2000)
10.1016/S0076-6879(96)68030-6
"NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms.
L. Keefer (1996)
10.1016/0960-894X(96)00484-2
Glyco-S-nitrosothiols, a novel class of NO donor compounds
J. Ramirez (1996)
10.1021/TX00041A007
DNA sequence changes induced by two nitric oxide donor drugs in the supF assay.
M. Routledge (1994)
10.1021/JO9901539
Piperazine as a Linker for Incorporating the Nitric Oxide-Releasing Diazeniumdiolate Group into Other Biomedically Relevant Functional Molecules
J. Saavedra (1999)
10.1016/S0040-4039(00)02158-4
The synthesis and cytotoxicity of fructose-1-SNAP, a novel fructose conjugated S-nitroso nitric oxide donor
Yongchun Hou (2001)
10.1021/JA01486A021
The Reaction of Nitrogen(II) Oxide with Diethylamine
R. S. Drago (1960)
10.1055/S-0038-1649644
Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect.
J. Diodati (1993)
10.1021/JM9903850
Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: in vitro antileukemic activity.
J. Saavedra (2000)



This paper is referenced by
10.1007/s12272-013-0047-0
Synergistic interaction of β-galactosyl-pyrrolidinyl diazeniumdiolate with cisplatin against three tumor cells
Lingling Deng (2013)
10.1039/c3cc40869h
Synthesis of cephalosporin-3'-diazeniumdiolates: biofilm dispersing NO-donor prodrugs activated by β-lactamase.
N. Yepuri (2013)
10.1016/j.jconrel.2015.05.283
Enzyme-functionalized vascular grafts catalyze in-situ release of nitric oxide from exogenous NO prodrug.
Zhihong Wang (2015)
10.1039/c2cc32284f
Nitrous oxide as a primary product in base-mediated β-elimination reactions of diazeniumdiolated benzylamine derivatives.
Debanjan Biswas (2012)
10.1039/c9cc05266f
Novel α-ketoamide based diazeniumdiolates as hydrogen peroxide responsive nitric oxide donors with anti-lung cancer activity.
Junjie Fu (2019)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.1080/00397910903074079
Arylation of Sensitive 1-(Pyrrolidin-1-yl)-diazen-1-ium-diolate in Ionic Liquids
C. Velázquez (2010)
10.1039/C000152J
Tailored Synthesis of Nitric Oxide-Releasing Polyurethanes Using O-Protected Diazeniumdiolated Chain Extenders.
M. Reynolds (2010)
10.1021/OL048397P
Sialated diazeniumdiolate: a new sialidase-activated nitric oxide donor.
T. B. Cai (2004)
10.1021/jm8000482
Hydrolytic Reactivity Trends among Potential Prodrugs of the O2-Glycosylated Diazeniumdiolate Family. Targeting Nitric Oxide to Macrophages for Antileishmanial Activity
C. Valdez (2008)
Abgrenzung der verschiedenen Schadensersatzansprüche
Long Jiang (2001)
NSAID-Diazeniumdiolate - Hybridarzneistoffe als direkte NO- Donatoren
T. Winkler (2006)
10.1039/C8QM00013A
The renaissance of nitric oxide: from improvement of stability to enhancement of endocytosis
F. Jia (2018)
10.1002/CHIN.200134212
Glycosylated Diazeniumdiolates: A Novel Class of Enzyme‐Activated Nitric Oxide Donors.
X. Wu (2001)
10.1039/c7cc08526e
A small molecule for theraNOstic targeting of cancer cells.
G. Ravikumar (2017)
10.1038/sj.bjp.0707224
Recent developments in nitric oxide donor drugs
M. Miller (2007)
10.1517/13543784.11.5.587
Nitric oxide donor drugs: current status and future trends
D. Webb (2002)
10.1248/BPB.29.1239
Delivery of Nitric Oxide Released from β-Gal-NONOate Activation by β-Galactosidase and Its Activity against Escherichia coli
C. Chen (2006)
10.1021/jm400393u
Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Junjie Fu (2013)
10.1146/ANNUREV.PHARMTOX.43.100901.135831
Progress toward clinical application of the nitric oxide-releasing diazeniumdiolates.
L. Keefer (2003)
10.1517/13543776.18.10.1111
NO donor hybrid compounds as multifunctional therapeutic agents
L. Fang (2008)
10.1002/cbic.201700683
Npom‐Protected NONOate Enables Light‐Triggered NO/cGMP Signalling in Primary Vascular Smooth Muscle Cells
Anna S Stroppel (2018)
10.1002/cmdc.201700762
Application of Mono‐ and Disaccharides in Drug Targeting and Efficacy
S. Yu-an (2018)
10.1039/c0cc00849d
Nitrogen-bound diazeniumdiolated amidines.
Debanjan Biswas (2010)
10.1002/ARDP.200500262
A Glycosylated Nitric Oxide Donor, β‐Gal‐NONOate, and its Site‐specific Antitumor Activity
C. Chen (2006)
10.1002/adma.201702859
Therapeutic-Gas-Responsive Hydrogel.
J. Park (2017)
10.1039/c2ob25252j
Glycosylated diazeniumdiolate-based oleanolic acid derivatives: synthesis, in vitro and in vivo biological evaluation as anti-human hepatocellular carcinoma agents.
Zhangjian Huang (2012)
10.1002/adma.201805818
Nitric-Oxide-Releasing Biomaterial Regulation of the Stem Cell Microenvironment in Regenerative Medicine.
Adam C Midgley (2019)
10.1002/advs.201701043
Progress and Promise of Nitric Oxide‐Releasing Platforms
T. Yang (2018)
10.1016/S0960-894X(03)00242-7
Synthesis of beta-lactamase activated nitric oxide donors.
X. Tang (2003)
10.1002/CHEM.200500325
Nitrosation of sugar oximes: preparation of 2-glycosyl-1-hydroxydiazene-2-oxides.
J. Brand (2005)
10.1039/c7cc00213k
O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma.
Chengfeng Bai (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar